Cost Savings from Reduced Hospitalizations with Use of Home Noninvasive Ventilation for COPD

Background: Although evidence suggests significant clinical benefits of home noninvasive ventilation (NW) for management of severe chronic obstructive pulmonary disease (COPD), economic analyses supporting the use of this technology are lacking. Objectives: To evaluate the economic impact of adopting home NIV, as part of a multifaceted intervention program, for severe COPD. Methods: An economic model was developed to calculate savings associated with the use of Advanced NW (averaged volume assured pressure support with autoexpiratory positive airway pressure; Trilogy100, Philips Respironics, Inc., Murrysville, PA) versus either no NW or a respiratory assist device with bilevel pressure capacity in patients with severe COPD from two distinct perspectives: the hospital and the payer. The model examined hospital savings over 90 days and payer savings over 3 years. The number of patients with severe COPD eligible for home Advanced NW was user-defined. Clinical and cost data were obtained from a quality improvement program and published reports. Scenario analyses calculated savings for hospitals and payers covering different COPD patient cohort sizes. Results: The hospital base case (250 patients) revealed cumulative savings of $402,981 and $449,101 over 30 and 90 days, respectively, for Advanced NW versus both comparators. For the payer base case (100,000 patients), 3-year cumulative savings with Advanced NIV were $326 million versus no NW and $1.04 billion versus respiratory assist device. Conclusions: This model concluded that adoption of home Advanced NW with averaged volume assured pressure support with autoexpiratory positive airway pressure, as part of a multifaceted intervention program, presents an opportunity for hospitals to reduce COPD readmission-related costs and for payers to reduce costs associated with managing patients with severe COPD on the basis of reduced admissions.